In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?
September 29th 2022With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.